Markets Weekahead

A broker reacts while trading at a stock brokerage firm in Mumbai September 29, 2008. REUTERS/Arko Datta/Files

Too good to last much longer

The markets have run up too fast too soon to sustain without a healthy correction. In the near term, global markets cues, FII activities and rupee movement remain the key, writes Ambareesh Baliga.  Full Article 

  • Most Popular
  • Most Shared

Reuters Showcase

Defence Pact

Defence Pact

Dassault Aviation, Reliance in defence pact.  Full Article 

Selling Citizenship

Selling Citizenship

SPECIAL REPORT - Passports... for a price.  Full Article 

A petrol bomb explodes near riot police during a huge anti-austerity demonstration in Athens' Syntagma (Constitution) square February 12, 2012. REUTERS/Yannis Behrakis

Greek Debt Crisis

Protesters battle Greek police as parliament decides austerity.  Full Article 

Bharti Fined

Bharti Fined

Burkina Faso fines telcos including Bharti over service faults.  Full Article 

Analysing Facebook

Analysing Facebook

Video: Jack & Suzy Welch: IPO hangover may change Facebook forever.  Video 

DLF Results

DLF Results

DLF Q3 net falls 45 pct, sees more gloom ahead.  Full Article 

Oil Demand

Oil Demand

IEA cuts 2012 oil demand growth forecast yet again.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Stock recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Matrix Laboratories says gets WHO approval for HIV durg

Related Topics

PICTURE GALLERY

A Hindu devotee with a pierced tongue takes part in a procession during the Thaipusam festival in Kochi February 7, 2012. REUTERS/Sivaram V

India this week

A selection of the best photos from the past seven days from India.  Slideshow 

» More slideshows

MUMBAI | Thu Feb 26, 2009 9:49am IST

MUMBAI (Reuters) - Matrix Laboratories Ltd said it got approval from the World Health Organisation (WHO) for generic version of a drug to treat the human immuno-deficiency virus (HIV).

The WHO approval enables Matrix to market Lopinavir or Ritonavir tablets in dosages of 200 mg or 50 mg in most countries outside the United States and Europe, the company said in a statement on Thursday.

The tablets are the generic version of Abott Laboratories' Kaltera tablets, it added.
Business
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.